Hybrid Solid-Liquid Phase Peptide Purification Technology Accelerates Large-Scale Peptide Production

Jun 05, 2026

Leave a message

news-1128-608

Limitations of Single-Phase Technologies Restrict Peptide Scale-Up

Traditional standalone solid-phase or liquid-phase workflows face obvious drawbacks in commercial production. Solid-phase synthesis struggles with high solvent consumption and poor scalability for long-sequence peptides, while liquid-phase methods require repeated complex separation steps. Cumulative by-products push up purification expenses, restricting affordable large-batch manufacturing of advanced cosmetic peptides.

 

Hybrid Technology Integrates Dual Advantages to Optimize Purification Workflow

The novel hybrid solid-liquid phase purification strategy merges high-purity fragment assembly from solid-phase routes and the cost efficiency of liquid-phase condensation. Target peptide fragments are pre-synthesized and pre-purified before liquid-phase cyclization and assembly. Intermediate separation reduces impurity accumulation, lowering the burden of final chromatographic purification and improving crude peptide quality.

news-1138-578

 

news-1130-587

Improved Yield & Cost Efficiency Boost Supply Chain Stability for Cosmetic Peptides

Manufacturers adopting this hybrid process report significantly elevated overall yields and reduced unit production costs. Less reliance on repeated high-performance liquid chromatography cuts solvent consumption and waste discharge. For cyclic peptides and multi-peptide portfolios, the technology enables consistent batch quality, helping raw material suppliers deliver stable supplies to mid-to-high-end cosmetic brands.

 

Technology Widens Accessibility for Complex Cyclic Peptide Ingredients

Complex cyclic peptides have long suffered from low cyclization efficiency and difficult impurity removal, limiting their market adoption. The integrated purification system suppresses intermolecular side reactions and simplifies the isolation of target cyclic molecules. More innovative cyclic peptide candidates under NMPA filing can move from lab research to commercial raw material supply at a faster pace.

news-1133-596

 

news-1137-593

Outlook: Continuous Process Upgrades Support Next-Generation Peptide Innovation

Industry developers keep refining hybrid purification parameters, targeting greener solvent systems and automated continuous production lines. Moving forward, the technology will be combined with biosynthetic pathways to further lower carbon footprints. Cost-effective mass production will unlock more formulation innovations mixing peptides with fungal extracts and advanced delivery carriers.

 

 

Send Inquiry